Stock Ideas
New
Stocks
Funds
Screener
Sectors
Watchlists
PRCT

PRCT - PROCEPT BioRobotics Corporation Stock Price, Fair Value and News

63.21USD-0.27 (-0.43%)Delayed as of 14 Jun 2024, 11:04 am ET

Market Summary

PRCT
USD63.21-0.27
Delayedas of 14 Jun 2024, 11:04 am
-0.43%

PRCT Alerts

  • 1 major insider sales recently.
  • Big jump in Revenue (Y/Y)
  • Losses in recent quarter

PRCT Stock Price

View Fullscreen

PRCT RSI Chart

PRCT Valuation

Market Cap

3.3B

Price/Earnings (Trailing)

-31.58

Price/Sales (Trailing)

20.88

Price/Free Cashflow

-25.87

PRCT Price/Sales (Trailing)

PRCT Profitability

Operating Margin

53.47%

Return on Equity

-39.15%

Return on Assets

-27%

Free Cashflow Yield

-3.87%

PRCT Fundamentals

PRCT Revenue

Revenue (TTM)

156.3M

Rev. Growth (Yr)

82.51%

Rev. Growth (Qtr)

2.2%

PRCT Earnings

Earnings (TTM)

-103.4M

Earnings Growth (Yr)

8.87%

Earnings Growth (Qtr)

5.63%

Breaking Down PRCT Revenue

52 Week Range

29.5263.42
(Low)(High)

Last 7 days

-7.2%

Last 30 days

-2.9%

Last 90 days

33.3%

Trailing 12 Months

82.7%

How does PRCT drawdown profile look like?

PRCT Financial Health

Current Ratio

8.52

Debt/Equity

0.19

Debt/Cashflow

-2.03

PRCT Investor Care

Shares Dilution (1Y)

14.15%

Diluted EPS (TTM)

-2.12

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2024156.3M000
202385.2M101.6M116.4M136.2M
202241.5M49.7M61.4M75.0M
202114.4M21.1M27.8M34.5M
20200007.7M

Tracking the Latest Insider Buys and Sells of PROCEPT BioRobotics Corporation

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Jun 10, 2024
shiblaq hisham
acquired
118,770
4.56
26,046
evp, chief comm. officer
Jun 10, 2024
shiblaq hisham
sold
-1,777,500
68.2446
-26,046
evp, chief comm. officer
Jun 04, 2024
desai antal rohit
acquired
-
-
1,376
-
Jun 04, 2024
dodrill amy m.
acquired
-
-
1,376
-
Jun 04, 2024
garrett mary
acquired
-
-
1,376
-
Jun 04, 2024
sandoval elisabeth
acquired
-
-
1,376
-
Jun 04, 2024
harris taylor c.
acquired
-
-
1,376
-
Jun 04, 2024
harris taylor c.
acquired
422,429
5.18
81,550
-
Jun 04, 2024
krummel thomas m
acquired
-
-
1,376
-
Jun 04, 2024
wood larry l
acquired
-
-
1,376
-

1–10 of 50

Which funds bought or sold PRCT recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
May 16, 2024
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
reduced
-3.35
272,220
2,220,490
-%
May 16, 2024
CASTLEARK MANAGEMENT LLC
new
-
2,841,160
2,841,160
0.12%
May 16, 2024
JANE STREET GROUP, LLC
reduced
-58.31
-3,101,820
2,999,650
-%
May 15, 2024
PERCEPTIVE ADVISORS LLC
new
-
10,410,800
10,410,800
0.18%
May 15, 2024
VOLORIDGE INVESTMENT MANAGEMENT, LLC
new
-
11,218,500
11,218,500
0.04%
May 15, 2024
Bellevue Group AG
added
0.54
6,884,580
43,989,400
0.67%
May 15, 2024
QUADRANT CAPITAL GROUP LLC
unchanged
-
210
1,384
-%
May 15, 2024
OCONNOR, A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS (LLC)
reduced
-32.97
-173,155
653,184
0.05%
May 15, 2024
TWO SIGMA INVESTMENTS, LP
added
449
10,226,100
12,091,800
0.03%
May 15, 2024
Voya Investment Management LLC
reduced
-15.92
-5,660
658,027
-%

1–10 of 38

Are Funds Buying or Selling PRCT?

Are funds buying PRCT calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own PRCT
No. of Funds

Unveiling PROCEPT BioRobotics Corporation's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
May 22, 2024
cpmg inc
1.9%
958,334
SC 13D/A
May 07, 2024
cpmg inc
6.3%
3,222,345
SC 13D/A
Feb 14, 2024
t. rowe price investment management, inc.
7.3%
3,695,027
SC 13G
Feb 13, 2024
vanguard group inc
8.29%
4,184,585
SC 13G/A
Feb 09, 2024
fmr llc
-
0
SC 13G/A
Jan 26, 2024
blackrock inc.
6.6%
3,357,638
SC 13G
Feb 14, 2023
viking global investors lp
0.0%
0
SC 13G/A
Feb 14, 2023
t. rowe price investment management, inc.
6.0%
2,697,885
SC 13G
Feb 09, 2023
fmr llc
-
0
SC 13G/A
Feb 09, 2023
vanguard group inc
7.23%
3,234,864
SC 13G

Recent SEC filings of PROCEPT BioRobotics Corporation

View All Filings
Date Filed Form Type Document
Jun 12, 2024
4
Insider Trading
Jun 10, 2024
144
Notice of Insider Sale Intent
Jun 06, 2024
4
Insider Trading
Jun 06, 2024
4
Insider Trading
Jun 06, 2024
4
Insider Trading
Jun 06, 2024
4
Insider Trading
Jun 06, 2024
4
Insider Trading
Jun 06, 2024
4
Insider Trading
Jun 06, 2024
4
Insider Trading
Jun 06, 2024
4
Insider Trading

Peers (Alternatives to PROCEPT BioRobotics Corporation)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
180.0B
40.3B
-0.56% 0.17%
31.97
4.46
-2.84% -3.00%
67.0B
19.7B
-1.30% -8.44%
50.29
3.4
4.82% -17.56%
20.4B
3.9B
-2.39% -15.83%
44.18
5.21
5.72% 46.72%
17.2B
14.9B
-4.28% -22.37%
6.49
1.15
2.98% 207.68%
MID-CAP
9.7B
3.5B
-1.42% 26.61%
30.89
2.73
6.16% 35.06%
8.5B
12.4B
-8.96% -11.44%
21.87
0.68
-0.93% -18.83%
8.0B
2.6B
-4.13% -24.00%
-24.93
3.09
-6.25% -68.58%
5.5B
3.9B
-5.09% -29.87%
-58.05
1.41
0.23% 90.80%
3.4B
387.1M
-0.21% 32.29%
-215.63
8.87
30.82% 65.57%
2.0B
6.6B
-10.10% -15.73%
10.59
0.31
2.78% -0.87%
SMALL-CAP
1.5B
3.2B
18.01% 16.23%
-2.22
0.48
7.94% -1695.32%
385.1M
169.3M
1.48% -3.53%
-5.01
2.28
7.49% -244.90%
249.1M
324.0M
0.65% -42.87%
-1.3
0.77
-3.19% -337.41%
50.6M
50.5M
3.55% -78.84%
-2.22
1
14.25% -10.06%
1.8M
3.7M
-17.65% -79.41%
-0.15
0.48
5.77% 8.23%

PROCEPT BioRobotics Corporation News

Latest updates
MarketBeat40 hours ago
Investor's Business Daily01 May 202407:00 am

PROCEPT BioRobotics Corporation Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Thousands)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q3
Revenue2.2%45.0044.0035.0033.0024.0024.0020.0017.0014.0010.009.008.007.005.002.00
Cost Of Revenue-12.6%20.0022.0016.0015.0012.0013.0010.008.007.006.004.005.004.00-2.00
Gross Profit17.8%25.0021.0019.0018.0012.0011.0010.008.008.005.004.004.004.00--0.03
Operating Expenses3.7%53.0051.0044.0044.0041.0036.0032.0026.0023.0021.0017.0017.0015.00-11.00
  S&GA Expenses9.0%40.0036.0033.0032.0030.0026.0025.0020.0018.0016.0012.0012.0010.00-7.00
  R&D Expenses-9.7%13.0014.0012.0012.0011.0010.008.007.005.005.005.004.005.00-4.00
Interest Expenses-7.1%1.001.001.001.001.001.001.001.001.001.001.001.001.00-1.00
Net Income5.6%-25.96-27.50-24.62-25.28-28.48-28.17-22.61-19.18-17.18-18.35-14.10-14.58-12.82-15.28-12.01
Net Income Margin15.0%-0.66*-0.78*-0.92*-1.03*-1.16*-1.16*-1.26*-1.38*-1.55*-1.74*-2.04*-2.59*-3.66*-6.87*-
Free Cashflow-2.2%-34.23-33.51-24.72-33.71-41.27-26.04-21.36-17.34-18.29-16.81-12.86-13.02-15.24--
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32020Q4
Assets-5.4%383405421272284309324311321337351126
  Current Assets-6.1%329351369230246273289298308326339110
    Cash Equivalents-12.3%226257287150181226249270284304320101
  Inventory4.7%42.0040.0042.0043.0039.0029.0022.0014.0013.0013.0010.007.00
  Net PPE-0.9%28.0029.0027.0016.0012.009.005.004.005.005.006.008.00
Liabilities-4.1%11912412211711111210372.0068.0070.0068.0065.00
  Current Liabilities-15.8%39.0046.0041.0036.0033.0035.0027.0019.0015.0016.0014.0015.00
  Long Term Debt0.1%51.0051.0051.0051.0051.0051.0051.0051.0050.0050.0050.0044.00
    LT Debt, Current------------5.00
    LT Debt, Non Current0.1%51.0051.0051.0051.0051.0051.0051.0051.0050.0050.0050.0044.00
Shareholder's Equity-6.0%264281299156173197221239253267283-
  Retained Earnings-5.7%-480-454-427-402-377-348-320-297-278-261-243-201
  Additional Paid-In Capital1.3%74473572655855054654153753252952719.00
Accumulated Depreciation30.9%5.004.00---9.00--7.007.006.005.00
Shares Outstanding1.2%51.0051.0050.0045.0045.0044.0045.0044.0044.0016.007.005.00
Float----1,400---1,000----
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q3
Cashflow From Operations-30.2%-32,286-24,793-18,943-28,339-35,928-25,174-19,851-17,126-18,231-16,476-12,751-12,909-15,198--
  Share Based Compensation25.6%6,2564,9815,3265,1033,7242,8853,2242,6761,5521,496925725650--
Cashflow From Investing77.7%-1,946-8,715-5,780-5,372-5,339-866-1,514-218-55.00-332-111-110-39.00--
Cashflow From Financing-9.8%2,5862,866162,1192,430380-1,3187772,8621,291644174,12286,1251,225--
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

PRCT Income Statement

2024-03-31
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Income Statement [Abstract]  
Revenue$ 44,539$ 24,404
Cost of sales19,50511,913
Gross profit25,03412,491
Operating expenses:  
Research and development13,08410,737
Selling, general and administrative39,59930,131
Total operating expenses52,68340,868
Loss from operations(27,649)(28,377)
Interest expense(1,045)(886)
Interest and other income, net2,737779
Net loss$ (25,957)$ (28,484)
Net loss per share, basic (in dollars per share)$ (0.51)$ (0.63)
Net loss per share, diluted (in dollars per share)$ (0.51)$ (0.63)
Weighted-average common shares used to compute net loss per share attributable to  
Common shareholders, Basic (in shares)51,01145,066
Common shareholders, Diluted (in shares)51,01145,066
Other comprehensive loss:  
Unrealized gain on cash equivalents$ 29$ 21
Comprehensive loss$ (25,928)$ (28,463)

PRCT Balance Sheet

2024-03-31
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets:  
Cash and cash equivalents$ 225,576$ 257,222
Accounts receivable, net56,08148,376
Inventory41,62239,756
Prepaid expenses and other current assets5,9075,213
Total current assets329,186350,567
Restricted cash, non-current3,0383,038
Property and equipment, net28,48828,748
Operating lease right-of-use assets, net19,89220,241
Intangible assets, net1,1361,204
Other assets1,160919
Total assets382,900404,717
Current liabilities:  
Accounts payable10,08413,499
Accrued compensation11,46916,885
Deferred revenue5,8605,656
Operating lease, current1,7011,683
Loan facility derivative liability, current1,9141,886
Other current liabilities7,6226,318
Total current liabilities38,65045,927
Long-term debt51,37151,339
Operating lease, non-current28,31526,182
Other liabilities517517
Total liabilities118,853123,965
Commitments and contingencies (see Note 11)
Stockholders’ equity:  
Preferred stock, $0.00001 par value; Authorized shares: 10,000 at March 31, 2024 and December 31, 2023, Issued and outstanding shares: none at March 31, 2024 and December 31, 202300
Common stock, $0.00001 par value; Authorized shares: 300,000 at March 31, 2024 and December 31, 2023 Issued and outstanding shares: 51,393 and 50,771 at March 31, 2024 and December 31, 2023, respectively00
Additional paid-in capital744,463735,240
Accumulated other comprehensive gain11384
Accumulated deficit(480,529)(454,572)
Total stockholders’ equity264,047280,752
Total liabilities and stockholders’ equity$ 382,900$ 404,717
PRCT
PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). The company also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in Redwood City, California.
 CEO
 WEBSITEprocept-biorobotics.com
 INDUSTRYMedical Instruments & Supplies
 EMPLOYEES428

PROCEPT BioRobotics Corporation Frequently Asked Questions


What is the ticker symbol for PROCEPT BioRobotics Corporation? What does PRCT stand for in stocks?

PRCT is the stock ticker symbol of PROCEPT BioRobotics Corporation. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of PROCEPT BioRobotics Corporation (PRCT)?

As of Thu Jun 13 2024, market cap of PROCEPT BioRobotics Corporation is 3.26 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of PRCT stock?

You can check PRCT's fair value in chart for subscribers.

What is the fair value of PRCT stock?

You can check PRCT's fair value in chart for subscribers. The fair value of PROCEPT BioRobotics Corporation is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of PROCEPT BioRobotics Corporation is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for PRCT so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is PROCEPT BioRobotics Corporation a good stock to buy?

The fair value guage provides a quick view whether PRCT is over valued or under valued. Whether PROCEPT BioRobotics Corporation is cheap or expensive depends on the assumptions which impact PROCEPT BioRobotics Corporation's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for PRCT.

What is PROCEPT BioRobotics Corporation's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Jun 13 2024, PRCT's PE ratio (Price to Earnings) is -31.58 and Price to Sales (PS) ratio is 20.88. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. PRCT PE ratio will change depending on the future growth rate expectations of investors.